Are selective COX 2 inhibitors superior to traditional MAIM? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs

被引:9
作者
Budenholzer, BR [1 ]
机构
[1] Grp Hlth Cooperat, Clin Enhancement & Dev Network Serv Div, Spokane, WA 99210 USA
来源
BRITISH MEDICAL JOURNAL | 2002年 / 325卷 / 7356期
关键词
D O I
10.1136/bmj.325.7356.161
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:161 / 161
页数:1
相关论文
共 2 条
[1]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[2]   Are selective COX 2 hihibitors superior to traditional non steroidal anti-inflammatory drugs?: Adequate analysis of the CLASS trial indicates that this may not be the case [J].
Jüni, P ;
Rutjes, AWS ;
Dieppe, PA .
BRITISH MEDICAL JOURNAL, 2002, 324 (7349) :1287-1288